基本介紹
- 中文名：齊琦
- 國籍：中國
- 民族：漢
- 出生地：河南省
- 畢業院校：中國藥科大學
- 學位/學歷：博士
- 職業：教師
- 專業方向：藥理學
人物經歷,研究方向,主要成就,獲獎記錄,社會任職,
人物經歷
2018.6-2023，暨南大學醫學院藥理系 教授
2016.11-2018.5，埃默里大學醫學院藥理系化學生物學研發中心 Instructor (美國)
2015.3-2016.10，埃默里大學醫學院藥理系化學生物學研發中心Research Associate (美國)
2010.8-2015.2，埃默里大學醫學院病理和實驗醫學系博士後(美國)
2009.8-2010.7，西維吉尼亞大學醫學院生理系倫道夫瑪麗巴布癌症中心博士後(美國)
2006-2009，中國藥科大學, 藥理學博士學位
2003-2006，中國藥科大學, 藥理學碩士學位
1999-2003，鄭州大學, 藥學學士學位
研究方向
1、抗腫瘤化合物篩選，活性及機制研究；
2、腫瘤相關蛋白功能及信號傳導通路方面的研究；
3、基於蛋白-蛋白相互作用的靶標的發現和研究
主要成就
齊琦，暨南大學基礎醫學院與公共衛生學院藥理學系，教授，博導。致力於藥理學及腫瘤細胞生物研究。迄今為止發表論文90篇，SCI論文84篇，其中包括國際知名雜誌PNAS, Oncogene, Mol Psychiatry, JMC, Science Signaling, JBC在內SCI第一/通訊作者論文30篇 (總影響因子達到172.768年公布)。研究成果獲得國內外同行的廣泛關注和高度肯定。現是包括Cancer research，Cancer letters，Acta Pharmaceutica Sinica B，Biochemical Pharmacology，Molecular Pharmacology在內的30家SCI收錄雜誌的特邀審稿人。榮獲2016，2018及2020年度中國藥理學學會會刊 Acta Pharmacologica Sinica（中科院一區）傑出審稿人獎。Molecular and Cellular Biochemistry編委，《中國臨床藥理學及治療學》青年編委；《腫瘤藥理學》（2008，北京，化學工業出版）《藥理學》（2021，北京，中國醫藥科技出版社）教材編委。主持國家自然科學基金面上項目一項，廣州市基礎與套用基礎研究項目一項。骨幹成員參與國家重點研發計畫一項。國家自然科學基金和廣東省自然科學基金評審專家。中國抗癌協會抗癌藥物專業委員會青年委員會副主任委員，廣東省藥理學會腫瘤藥理學專業委員會常務委員，廣東省藥理學會藥物篩選與評價專業委員會常務委員，廣東省抗癌協會抗腫瘤藥物專業委員會委員，美國癌症研究協會，國際化學生物學學會，中國細胞生物學學會，中國藥理學會及中國生物化學與分子生物學會會員。。
主要論文
1.Cao Q, Luo S, Yao W, Qu Y, Wang N, Hong J, Murayama S, Zhang Z, Chen J, Hashimoto K, Qi Q, Zhang JC. Suppression of abnormal α-synuclein expression by activation of BDNF transcription ameliorates Parkinson’s disease-like pathology. Mol Ther Nucleic Acids. 2022 May 23. (Corresponding author)
2.Yao W, Cao Q, Luo S, He L, Yang C, Chen J, Qi Q, Hashimoto K, Zhang JC. Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. Mol Psychiatry. 2021 Nov 24;. doi: 10.1038/s41380-021-01377-7. (Corresponding author)
3.Tang R, Cao QQ, Hu SW, He LJ, Du PF, Chen G, Fu R, Xiao F, Sun YR, Zhang JC, Qi Q. Sulforaphane activates anti-inflammatory microglia, modulating stress resilience associated with BDNF transcription. Acta Pharmacol Sin. 2022 Apr;43(4):829-839. (Corresponding author)
4.Liu C, Yang D, Wang H, Hu S, Xie X, Zhang L, Jia H, Qi Q. MicroRNA-197-3p mediates damage to human coronary artery endothelial cells via targeting TIMP3 in Kawasaki disease. Mol Cell Biochem. 2021 Dec;476(12):4245-4263. (Corresponding author)
5.Li CL, Li J, Gong S, Huang M, Li R, Xiong G, Wang F, Zou Q, Qi Q, Yin X. Targeting the ILK/YAP axis by LFG-500 blocks epithelial-mesenchymal transition and metastasis. Acta Pharmacol Sin. Acta Pharmacol Sin. 2021 Nov;42(11):1847-1859. (Corresponding author)
6.Li Z, Su J, Sun M, Song J, Sun H, Fan J, Chen G, Shan C, Qi Q, Zhang S. Octamer transcription factor-1 induces the Warburg effect via up-regulation of hexokinase 2 in non-small cell lung cancer. Mol Cell Biochem. 2021 Sep;476(9):3423-3431. (Corresponding author)
7.Yao W, Lin S, Su J, Cao Q, Chen Y, Chen J, Zhang Z, Hashimoto K, Qi Q, Zhang JC. Activation of BDNF by transcription factor Nrf2 contributes to antidepressant-like actions in rodents. Transl Psychiatry. 2021 Feb 24;11(1):140. (Corresponding author)
8.Xu M, Qi Q, Men L, Wang S, Li M, Xiao M, Chen X, Wang S, Wang G, Jia H, Liu C. Berberine protects Kawasaki disease-induced human coronary artery endothelial cells dysfunction by inhibiting of oxidative and endoplasmic reticulum stress. Vascul Pharmacol. 2020 Apr;127:106660. (Co-first author)
9.Li X, Tang X, Su J, Xu G, Zhao L, Qi Q. Involvement of E-cadherin/AMPK/mTOR axis in LKB1-induced sensitivity of non-small cell lung cancer to gambogic acid. Biochem Pharmacol. 2019 Sep 9;169:113635. (Corresponding author)
10.Qi Q, Obianyo O, Du Y, Fu H, Li S, Ye K. Blockade of asparagine endopeptidase inhibits cancer metastasis. J Med Chem. 2017 Sep 14;60(17):7244-7255.
11.Qi Q, Kang SS, Zhang S, Baker SJ, Fu H, Brat DJ, Ye K. Co-amplification of Phosphoinositide 3-kinase enhancer A and Cyclin-dependent kinas 4 Triggers Glioblastoma Progression. Oncogene. 2017 Aug 10;36(32):4562-4572.
12.Qi Q, Li DY, Luo HR, Guan KL, Ye K. Netrin-1 exerts oncogenic activities through enhancing Yes-associated protein stability. Proc Natl Acad Sci U S A. 2015 Jun 9;112(23):7255-60.
13.Qi Q, He K, Liu X, Pham C, Meyerkord C, Fu H. Ye K. Disrupting the PIKE-A/Akt interaction inhibits glioblastoma cell survival, migration, invasion, and colony formation. Oncogene. 2013 Feb 21;32(8):1030-40.
14.Qi Q, Liu X, Daniel Brat, Ye K. Merlin sumoylation is required for its tumor suppressor activity. Oncogene. 2014 Oct 9;33(41):4893-903.
15.Qi Q, Liu X, Li S, Joshi HC, Ye K. Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth. Acta Pharmacol Sin. 2013 Jul;34(7):930-8.
16.He K, Qi Q, Chan CB, Xiao G, Liu X, Tucher-Burden C, Wang L, Mao H, Lu X, McDonald F, Luo H, Fan Q, Weiss W, Sun S, Brat D, Wang L, Mao H, Fu H, Tao H, Ye K. Blockade of Glioma Proliferation Through Allosteric Inhibition of JAK2. Science signal. 2013 Jul 9;6(283):ra55. (Co-first author)
17.Qi Q, Ye K. The roles of PIKE in tumorigenesis. Acta Pharmacol Sin. 2013 Aug;34(8):991-7.
18.Qi Q, He K, Yoo MH, Chan CB, Liu X, Zhang Z, Olson JJ, Xiao G, Wang L, Mao H, Fu H, Tao H, Ye K. Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases. J Biol Chem. 2012 Feb 24;287(9):6113-27. (Co-first author)
19.Qi Q, Lu N, Li C, Zhao J, Liu W, You Q, Guo Q. Involvement of RECK in gambogic acid induced anti-invasive effect in A549 human lung carcinoma cells. Mol Carcinog. 2015 Jun;54 Suppl 1:E13-25.
20.Qi Q, Gu H, Yang Y, Lu N, Zhao J, Liu W, Ling H, You QD, Wang X, Guo Q. Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med. 2008 Dec;86(12):1367-77.
21.Qi Q, Lu N, Wang XT, Gu HY, Yang Y, Liu W, Li C, You QD, Guo QL. Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol. 2008 Oct;86(5):386-95.
22.Qi Q, You Q, Gu H, Zhao L, Liu W, Lu N, Guo Q. Studies on the toxicity of gambogic acid in rats. J Ethnopharmacol. 2008 May 22;117(3):433-8.
23.Qi Q, Peng J, Liu W, You Q, Yang Y, Lu N, Wang G, Guo Q. Toxicological studies of wogonin in experimental animals. Phytother Res. 2009 Mar;23(3):417-22.
24. Li C, Qi Q, Lu N, Dai Q, Li F, You QD, Guo QL. Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol. 2012 Dec;90(6):718-30. (Co-first author)
25.Li C, Lu N, Qi Q, Li F, Ling Y, Chen Y, Qin Y, Li Z, Zhang H, You Q, Guo Q. Gambogic acid inhibits tumor cell adhesion by suppressing integrin β1 and membrane lipid rafts-associated integrin signaling pathway. Biochem Pharmacol. 2011 Dec 15;82(12):1873-83. (Co-first author)
26.Peng J, Qi Q, You Q, Hu R, Liu W, Feng F, Wang G, Guo Q. Subchronic toxicity and plasma pharmacokinetic studies on wogonin, a natural flavonoid, in Beagle dogs. J Ethnopharmacol. 2009 Jul 15;124(2):257-62. (Co-first author)
獲獎記錄
Acta Pharmacologica Sinica （A1-1區）突出貢獻獎，2020
Acta Pharmacologica Sinica 突出貢獻獎，2018
Acta Pharmacologica Sinica 突出貢獻獎，2016
社會任職
專業學會服務
中國抗癌協會抗癌藥物專業委員會青年委員會 副主任委員
廣東省藥理學會腫瘤藥理學專業委員會 常委
廣東省抗癌協會抗腫瘤藥物專業委員會 委員
專業學會會員
美國癌症研究協會， AACR
國際化學生物學學會， ICBS
中國細胞生物學學會，CSCB
中國藥理學會，CNPHARS
中國生物化學與分子生物學會，CSBMB
受邀評審專家
國家自然科學基金
廣東省自然科學基金
學術雜誌編委
《Molecular and Cellular Biochemistry》(IF:2.883);
《中國臨床藥理學與治療學》
擔任28家國際專業雜誌特邀審稿人
Cancer Research; Acta Pharmaceutica Sinica B; Cell Death & Disease; Free Radical Biology and Medicine; Journal of Experimental & Clinical Cancer Research; Laboratory Investigation; Journal of Molecular Medicine; Journal of Cellular and Molecular Medicine; Biochemical Pharmacology; Frontiers in Pharmacology; Molecular Pharmacology; Food and Chemical Toxicology; Investigational New Drugs; BMC Cancer; Toxicology; Acta Pharmacologica Sinica; Basic &Clinical Pharmacology & Toxicology; OncoTargets and Therapy; Journal of Cellular Biochemistry; European Journal of Pharmacology; PLOS One; Molecular and Cellular Biochemistry; Pharmacological Reports; Cancer Management and Research; Oncology Letters; Journal of Oncology; Neoplasma; Molecular Medicine Reports;
